Application of bacteroides fragilis 839 to preparation of medicine and food for treating or adjunctively treating immune-related diseases

A technology for immune-related diseases and Bacteroides fragilis, applied in the field of bioengineering, can solve the problems of increased tumor risk, high price, and short effective maintenance time, and achieve important application value

Active Publication Date: 2021-04-02
大连图腾生命科学发展有限公司 +1
View PDF9 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the treatment of these immune-related diseases is very difficult
Currently commonly used methods are: (1) Immunosuppressants, such as glucocorticoids, cyclophosphamide, cyclosporine, mycophenolate mofetil, etc.: have a strong inhibitory effect on various immune cells, but long-term use Then continue to suppress immunity, have greater side effects, and increase the risk of tumors
(2) Antibodies: immunoglobulins, monoclonal antibodies, these products have a short effective duration, unclear side effects, and are expensive
(3) Infusion of various immune cells and stem cell transplantation: not yet in clinical use
However, studies in other immune-related diseases have not been reported,

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bacteroides fragilis 839 to preparation of medicine and food for treating or adjunctively treating immune-related diseases
  • Application of bacteroides fragilis 839 to preparation of medicine and food for treating or adjunctively treating immune-related diseases
  • Application of bacteroides fragilis 839 to preparation of medicine and food for treating or adjunctively treating immune-related diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Example 1 Effects of Bacteroides fragilis 839 on Fragile X Syndrome-related Autistic Behaviors

[0044] 1. Experimental design

[0045] Weaning 3-week-old Fmr1 KO mice were selected as experimental subjects and divided into two groups, namely the blank control group (FmrlKO group) and the experimental group (BF839 group), with 15 mice in each group, 5 mice in one cage, and 3 cages in each group. . Among them, the mice in the experimental group (BF839 group) were Fmr1 knockout mice and drank the Bacteroides fragilis 839BF839 bacterial liquid for 4 weeks, and the blank control group (Fmrl KO group) were Fmr1 knockout mice. Autoclaved tap water was used for 4 weeks, and other feeding patterns were the same in both groups. Behavior experiments were performed when the mice were 7-8 weeks old.

[0046] 1. Open field experiment

[0047] The analysis box for the open field experiment is a square open box with a height of 30 cm and a bottom length of 70 cm. Place each mouse...

Embodiment 2

[0066]Example 2 Single-arm, open, self-controlled trial of Bacteroides fragilis 839BF839 on the therapeutic effect of psoriasis

[0067] 1. Inclusion criteria:

[0068] 1. Age 6-65 years old (including 6-65 years old), gender is not limited;

[0069] 2. Patients diagnosed with psoriasis vulgaris clinically and pathologically (refer to Zhao Bian's "Chinese Clinical Dermatology" for diagnostic criteria): the rash manifests as erythema, scales, thin film phenomenon, spotting and mainly on the extensor side of the body The symmetrical distribution characteristics of the skin; under the dermatoscope, dot-shaped, spherical, hairpin-like, and ring-shaped blood vessels can be seen on a bright red background, and white scales are diffusely distributed;

[0070] 3. PASI score ≤ 12 points, for mild to moderate psoriasis.

[0071] 2. Exclusion criteria:

[0072] 1. Age 65 years old;

[0073] 2. Taking hormones (excluding external use) or immunosuppressant drugs and other probiotic fo...

Embodiment 3

[0116] Example 3 Effect of probiotic Bacteroides fragilis 839BF839 on treatment of refractory autoimmune epilepsy

[0117] 1. Inclusion criteria:

[0118] 1. Diagnosed with chronic epilepsy: at least 2 non-provoked or non-reflexive seizures with an interval of >24 hours, and the EEG shows epileptiform abnormalities, which meet the definition of epilepsy in 2014.

[0119] 2. The patient is diagnosed with epilepsy with partial seizures, which cannot be adequately controlled by at least 2 AEDs in history. At enrollment, patients were receiving stable doses of 1-5 standard AEDs and had at least 4 localized attacks during a 4-week baseline period of at least >4 months duration

[0120] 3. Meet any of the following conditions:

[0121] (1) Previous diagnosis of "autoimmune encephalitis", including epilepsy after limbic lobe encephalitis positive for various nerve antibodies, autoimmune disease combined with epilepsy, primary autoimmune Resamussen encephalitis

[0122] (2) Once di...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of an application of bacteroides fragilis (BF) 839, in particular to an application of the bacteroides fragilis 839 to preparation of a medicine or food for treating or adjunctively treating immune-related diseases. The key effect of the bacteroides fragilis 839 in human intestinal tracts in treatment or adjuvant treatment of the immune-related diseasesis discovered for the first time, and the bacteroides fragilis 839 can be made into forms of pharmaceutical compositions, foods, health-care products or food additives by utilizing the key effect ofthe bacteroides fragilis 839 in the immune-related diseases. A pharmaceutical composition, a food, a health-care product or a food additive contains the bacteroides fragilis 839, can be used for treating the immune-related diseases, and has very important application value.

Description

technical field [0001] The invention belongs to the technical field of bioengineering, and specifically relates to the application of Bacteroides fragilis 839 in the preparation of medicines and food for the treatment or auxiliary treatment of immune-related diseases. Background technique [0002] Immune function is the general term for the body to recognize and remove foreign invading antigens and mutated or senescent cells in the body and maintain the stability of the body's internal environment. It can be summarized as follows: (1) Immune defense: prevent the invasion of external pathogens and eliminate the invading pathogens (such as bacteria, viruses, fungi and other microorganisms) and / or other harmful substances. The low immune defense function makes it impossible to resist external pathogen infection; ( 2) Immune surveillance: discover and remove "non-self" substances that appear in the body at any time, such as tumor cells produced by gene mutations, aging and dead ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/74A61P37/02A61P25/18A61P17/06A61P25/08A61P15/00A61P15/02A61P17/04A23L33/135
CPCA61K35/74A61P37/02A61P25/18A61P17/06A61P25/08A61P15/00A61P15/02A61P17/04A23L33/135A23V2002/00A23V2300/21A23V2200/324A23V2200/322A23V2200/318A23V2200/30A23V2250/206
Inventor 王蕾
Owner 大连图腾生命科学发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap